MSH6 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- MSH6 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb6442
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- MSH6 antibody Polyclonal Antibodies Primary antibodies
Related genes to: MSH6 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- MSH6 NIH gene
- Name:
- mutS homolog 6
- Previous symbol:
- GTBP
- Synonyms:
- -
- Chromosome:
- 2p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-29
- Date modifiied:
- 2019-04-23
Related products to: MSH6 antibody Polyclonal Antibodies Primary antibodies
Related articles to: MSH6 antibody Polyclonal Antibodies Primary antibodies
- Lynch syndrome (LS) is an inherited cancer predisposition syndrome associated with an increased risk of several malignancies, particularly colorectal cancer (CRC). The diagnosis of LS is typically based on family history and confirmed by genetic testing, most commonly involving pathogenic variants in mismatch repair genes, including , , , and . We report a proband who developed CRC at the age of 52 years and had a family history suggestive of LS. Immunohistochemical analysis revealed loss of MLH1 and PMS2 expression in the proband, and isolated loss of PMS2 expression in his maternal cousin. Whole-exome sequencing followed by Sanger sequencing identified a heterozygous c.1652A>C (p.Asn551Thr) variant in the proband, his maternal cousin, and four additional affected family members. Based on the clinical, pathological, and genetic findings, the extended family was diagnosed with LS. Taken together, c.1652A>C (p.N551T) variant may contribute to carcinogenesis, and its co-segregation with LS in this family provides supportive evidence for its potential pathogenicity. - Source: PubMed
Publication date: 2026/04/20
Duan ZhipeiHu ChengruCao TinghuaChen ChaoLi Yan - Since 2020, the UK National Institute for Health and Care Excellence (NICE) recommends screening for Lynch syndrome in all people newly diagnosed with endometrial cancer. Screening involves tumour testing for loss of the mismatch repair (MMR) proteins using immunohistochemistry (IHC), methylation testing and germline sequencing for Lynch syndrome according to a diagnostic algorithm. Here we review adherence to NICE guidance at a gynaecological cancer centre in North-West England. - Source: PubMed
Publication date: 2026/05/28
Johnson Jean-EllenMilliken SarahBolton JamesEvans D GarethLalloo FionaDavidson Emma J - Ovarian aging, marked by the gradual decline in both the number and quality of oocytes, significantly impacts women's reproductive lifespan and overall health. However, the biological mechanisms driving ovarian aging remain poorly understood and current treatment strategies are limited. - Source: PubMed
Publication date: 2026/05/28
Lian XuanSong ShuangLou ChenZhu MingLi YanLi WenjianJiang XintongWang GuiquanYang HaiyanWang LinHe LiyingMa YunlongDong XiChen YijieChang Hsun-MingZhu WenchengWang JiaYu YangWu YangZhao YueMu Liangshan - To investigate oncological and reproductive outcomes in patients with mismatch repair-deficient (MMRd) endometrial endometrioid carcinoma (EEC) or atypical endometrial hyperplasia (AEH) undergoing fertility-preserving treatment to inform clinical management of this molecular subtype. - Source: PubMed
Publication date: 2026/05/27
Zhang TianyuYang JieCao DongyanYu MeiWu HuanwenXiang YangZhang XinyueZong XuanZhang RundongJin XinyangZhang KezhenZheng JingYang Jiaxin - The aim of this study is to assess the mismatch repair (MMR) status and immunohistochemical changes in cases of recurrent endometrial cancer following primary surgery and to evaluate the impact of these changes on prognosis. Thirty-one patients diagnosed with endometrial cancer who underwent surgery and had pathologically confirmed recurrences were evaluated. Changes in MMR protein expression, estrogen receptor (ER)/progesterone receptor (PR), and p53 expression in primary surgery and recurrent tumor tissues were assessed using immunohistochemical methods. Prognostic factors influencing these parameters and survival data were investigated. : In the assessment of recurrent materials, there were four cases where the MLH-1&PMS-2 staining status changed from intact to loss and four cases that changed from loss to intact. No changes were observed in regard to MSH-2 &MSH-6 staining. The ratios of pMMR and dMMR following the primary surgery were 55% (n = 17) and 45% (n = 14), respectively. Four cases transitioned from pMMR to dMMR, and four cases transitioned from dMMR to pMMR. After recurrence, changes in the ER, PR, and P53 status were observed in seven, three, and three patients, respectively. : Changes in the MMR status, receptors, and P53 were observed. It is necessary to re-evaluate prognostic parameters via biopsies in recurring cases and to adjust rescue treatments accordingly. - Source: PubMed
Publication date: 2026/04/27
Guzeloz ZelihaKutlu OzceErdogan OzgurDemir GonulGulle Bugra TaygunSancı MuzafferErdogan MihribanTalu Canan Kelten